Information Provided By: 
Fly News Breaks for January 23, 2017
ADMA
Jan 23, 2017 | 14:43 EDT
As previously reported, Maxim upgraded ADMA Biologics to Buy from Hold and established a $13 price target. Analyst Jason Kolbert said ADMA announced it will acquire Biotest's 126,000 square foot immunoglobulin manufacturing assets where RI-002 is manufactured, putting it in a position to address the most complex issues related to manufacturing compliance. Kolbert said ADMA is now better positioned to drive changes needed to re-submit the BLA and integrate manufacturing costs that should increase margins.
News For ADMA From the Last 2 Days
There are no results for your query ADMA
